CCL2 and type 1 diabetes mellitus: We show that ECFCs from patients with T1D show exacerbated increases in mRNA levels of pro‐atherogenic/pro‐inflammatory genes (IL6 and CCL2) with IL‐1β treatment and reduced induction of the interferon marker (CXCL10) with TNFɑ compared to ECFCs from healthy donors.